Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
about
Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug deliveryAloe-emodin suppresses hypoxia-induced retinal angiogenesis via inhibition of HIF-1α/VEGF pathwayFormononetin, an active compound of Astragalus membranaceus (Fisch) Bunge, inhibits hypoxia-induced retinal neovascularization via the HIF-1α/VEGF signaling pathwayLight-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye.Nanoengineering of therapeutics for retinal vascular disease.Molecular pathogenesis of retinal and choroidal vascular diseases.Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in RabbitsInhibition of Hypoxia-Induced Retinal Angiogenesis by Specnuezhenide, an Effective Constituent of Ligustrum lucidum Ait., through Suppression of the HIF-1α/VEGF Signaling Pathway.HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.Probable Chemical Hypoxia Effects on Progress of CNV Through Induction of Promoter CpG Demethylation and Overexpression of IL17RC in Human RPE Cells.The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization.Systems biology of oxygen homeostasis.HIF is not essential for suppression of experimental tumor growth by mTOR inhibition.Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress.AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration.Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration.Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.Retinal and choroidal angiogenesis: a review of new targets.Prospects for early investigational therapies for sickle cell disease.
P2860
Q27007119-7A8A152E-2A9C-4206-9218-78D00FD7B414Q28820904-A5E04893-F9DF-4CDB-8714-CA698F1CE810Q28828440-FB6F3295-05F8-46AF-9E27-6F4A2986DEE3Q35262576-92C001F3-9E77-45DD-8B68-61985B1B1BF2Q35645705-7ECE64D5-AE65-45E2-8898-42449AF6109FQ36296789-1A87D16B-DE2C-4A5A-B13B-994BC210553DQ37383794-698FAC68-9FDC-4E15-AD48-116688B33EEDQ38724669-F6151150-2E61-402E-A046-62E993BCCC93Q38825960-209E79C3-D266-434B-AC9B-9760EF101686Q38829320-B470D9C2-1BA2-431C-ABEE-A5283B833095Q38924650-64C26FFE-4B64-42C0-93B2-447BA083BD3AQ39076235-C35DE837-A680-4AE6-AD07-9421F6C1A841Q39145122-6DF2756D-1BB7-4E17-9F03-404F47085EB0Q41396055-6A2A4EBA-48B2-47F8-A962-AF7C2C8A4E74Q41679754-E35855FC-DEF9-4B5A-8220-CC09D120430BQ47225954-B24FF711-8D1F-45CB-A4EE-EAC7842CDE73Q47442388-FDBC2334-CC3C-40E7-AFE9-51AFC0A7D81AQ47834991-AA712E82-FA9E-4796-9510-A7B17F379629Q49334226-400F883A-9C68-454A-8459-A21A87A30B35Q53098522-576607A5-D577-4A45-A644-D60324DEA973Q53608275-684DF790-F958-48E1-A579-5F4E9A3FD709
P2860
Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
@ast
Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
@en
type
label
Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
@ast
Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
@en
prefLabel
Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
@ast
Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
@en
P2093
P2860
P50
P1476
Sustained delivery of a HIF-1 antagonist for ocular neovascularization.
@en
P2093
Akiko Miki
Brian Oveson
Christopher Seidel
Daisuke Muramatsu
Jikui Shen
Mingsheng Wu
Noriyasu Hashida
P2860
P304
P356
10.1016/J.JCONREL.2013.10.008
P407
P577
2013-10-12T00:00:00Z